来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02105 来凯医药-B

休市中 09-11 16:08:55

6.015

-0.285

-4.52%

最高6.400	最低6.000	成交量104.40万
今开6.300	昨收6.300	日振幅6.35%
总市值27.19亿	流通市值27.19亿	总股本4.52亿
成交额633.53万	换手率0.23%	流通股本4.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"来凯医药-B","latestPrice":6.015,"timestamp":1789114135004,"preClose":6.3,"halted":0,"volume":1044000,"delay":0,"changeRate":-0.045238095238095265,"floatShares":451999999,"shares":451999999,"eps":-0.59,"marketStatus":"休市中","change":-0.285,"latestTime":"09-11 16:08:55","open":6.3,"high":6.4,"low":6,"amount":6335306,"amplitude":0.063492,"askPrice":6.03,"askSize":500,"bidPrice":6.01,"bidSize":41500,"shortable":3,"etf":0,"ttmEps":-0.26,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":7,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":6.3,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":0.8268651988092327,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105","defaultTab":"news","newsList":[{"id":"2665202703","title":"来凯医药-B(02105)合共发行27.3万股以满足根据2024年股份奖励计划授予的RSU的归属","url":"https://stock-news.laohu8.com/highlight/detail?id=2665202703","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665202703?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:18","pubTimestamp":1788869922,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B(02105)发布公告，于2026年9月8日，该公司合共发行27.3万股普通股以满足根据2024年股份奖励计划授予的RSU的归属。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155209452","title":"来凯医药-B：9月8日发行2,730,000股新股，已发行股本增至452,061,350股","url":"https://stock-news.laohu8.com/highlight/detail?id=1155209452","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155209452?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:16","pubTimestamp":1788869764,"startTime":"0","endTime":"0","summary":"来凯医药-B（02105）于2026年9月8日公告，因根据2024年股份奖励计划向公司董事及其他参与人授予的限制性股票单位（RSU）归属，公司于当日分别发行1,125,000股和1,605,000股普通股，合计发行2,730,000股。\n本次发行股份占公告前公司已发行股本449,331,350股的约0.2504%及0.3572%，发行价格均为每股0港元。发行完成后，公司已发行股本增至452,061,350股，库藏股仍为0股。\n公司董事会已对本次股份发行进行正式授权，并确认本次发行依据相关上市规则及适用法律规定进行，相关董事会决议及手续已履行。公告由公司秘书柯晨煜签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"来凯医药-B：9月8日发行2,730,000股新股，已发行股本增至452,061,350股","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149410627","title":"来凯医药-B更新8月股份变动月报表 股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1149410627","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149410627?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:12","pubTimestamp":1788513125,"startTime":"0","endTime":"0","summary":"来凯医药-B于2026年9月4日发布截至2026年8月31日的股份变动月报表。公告显示，公司当月注册股本及已发行股份均未发生变化，股本结构保持稳定。报告期末，公司已发行股份总数为449,331,350股，较上月底无任何增减调整。公告称，截至2026年8月末，公司就所发行的股份，已充分满足香港联交所主板上市规则所要求的公众持股量规定，并确认所有新增或变动均符合相关法规与上市要求，且获得董事会正式授权。公告由公司秘书柯晨煜签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664229418","title":"港股异动 | 来凯医药-B(02105.HK)尾盘涨超7% LAE118 I期临床完成首例受试者入组 许可协议最高5.27亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664229418","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664229418?lang=zh_cn&edition=full","pubTime":"2026-09-03 15:34","pubTimestamp":1788420853,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664882311","title":"港股异动 | 来凯医药-B(02105)早盘涨超9% LAE118的I期临床研究首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2664882311","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664882311?lang=zh_cn&edition=full","pubTime":"2026-09-01 09:46","pubTimestamp":1788227194,"startTime":"0","endTime":"0","summary":"消息面上，9月1日，来凯医药-B发布公告，集团已于中国启动LAE118用于治疗晚期实体瘤的I期临床研究的受试者招募，且已完成首例受试者入组。集团亦有权在无需额外对价的情况下，获得Vasque Bio已发行普通股最高达高双位数百分比的股权，或替代该等普通股的现金付款。如Vasque Bio达成符合特定条件的合资格战略合作或收购交易，集团将有权获得额外付款，金额最高可达该战略交易价值的50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","02105","BK4588","BK1161","VXUS","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664889447","title":"来凯医药-B(02105)：LAE118(一种新型的PI3Kα泛突变选择性抑制剂) I期临床研究首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2664889447","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664889447?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:19","pubTimestamp":1788221941,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B 发布公告，集团已于中国启动LAE118用于治疗晚期实体瘤的I期临床研究的受试者招募，且已完成首例受试者入组。集团亦有权在无需额 外 对 价 的 情 况 下 ， 获 得 Vasque Bio 已 发 行 普 通 股 最 高 达 高 双 位 数 百 分 比 的 股权，或替代该等普通股的现金付款。Vasque Bio主要专注于罕见疾病治疗药物的开发，集团则专注于在许可区域以外开 发LAE118 的肿瘤 疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664889441","title":"来凯医药-B(02105.HK)：LAE118(一种新型的PI3Kα泛突变选择性抑制剂) I期临床研究首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2664889441","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664889441?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:19","pubTimestamp":1788221941,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197062258","title":"来凯医药-B(02105)LAE118在华启动I期临床并完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1197062258","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197062258?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:15","pubTimestamp":1788221745,"startTime":"0","endTime":"0","summary":"来凯医药-B9月1日发布自愿公告称，公司自研PI3Kα泛突变选择性抑制剂LAE118已在中国启动治疗晚期实体瘤的I期临床研究，并完成首例受试者入组。LAE118目前已获得美国食品药物管理局及中国国家药品监督管理局药品审评中心的新药临床试验批准。公告披露，2026年6月，公司与Vasque Bio, Inc.签署独家许可协议。来凯医药-B提醒投资者，LAE118最终未必能够成功开发及商业化，投资者在买卖公司证券时需审慎行事。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662765641","title":"来凯医药-B发布中期业绩 其他收入2596.2万元同比增加30.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662765641","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662765641?lang=zh_cn&edition=full","pubTime":"2026-08-26 08:47","pubTimestamp":1787705220,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端来凯医药-B（02105）发布截至2026年6月30日止6个月的中期业绩，该集团取得取得其他收入2596.2万元（人民币，下同），同比增加30.41%；研发费用9700万元，同比减少7.79%；期内亏损254.9万元，同比减少98.03%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-08-26/doc-inipqxhc6330788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186487767","title":"来凯医药-B（02105）公布2026年中期业绩：收入1.50亿元，期内亏损显著收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1186487767","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186487767?lang=zh_cn&edition=full","pubTime":"2026-08-25 22:53","pubTimestamp":1787669581,"startTime":"0","endTime":"0","summary":"2026年8月25日，来凯医药-B发布截至2026年6月30日止六个月未经审计的中期业绩。期内，公司实现收入人民币150,277,000元，全部来自LAE118及LAE002对外授权交易。同期毛利为人民币129,415,000元；研发费用为人民币97,000,000元，同比减少7.8%。行政开支为人民币58,627,000元，同比增加38.5%。期内亏损大幅缩窄至人民币2,549,000元，公司将主要归因于对外授权收益的确认。截至2026年6月30日，公司持有现金及银行结余人民币941,820,000元，原到期日超过三个月的定期存款人民币180,660,000元，两项合计人民币1,122,480,000元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660105172","title":"来凯医药-B(02105.HK)：预计中期收入1.45亿元至1.55亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660105172","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660105172?lang=zh_cn&edition=full","pubTime":"2026-08-17 08:37","pubTimestamp":1786927022,"startTime":"0","endTime":"0","summary":"格隆汇8月17日丨来凯医药-B(02105.HK)发布公告，截至2026年6月30日止六个月(“报告期间”)，集团预期录得：(i)报告期间收入约为人民币1.45亿元至人民币1.55亿元，去年同期截至2025年6月30日止六个月(“相应期间”)则为零；及(ii)报告期间综合净亏损不多于人民币500万元，去年相应期间综合净亏损约为人民币1.3亿元，即亏损按年大幅减少约96%。\r\n\r\n　　报告期间收入预期增加及综合净亏损大幅收窄，主要归因于与Vasque Bio, Inc.就LAE118及与齐鲁制药有限公司就LAE002(afuresertib)的独家许可协议确认的收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260817/32336435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118228633","title":"来凯医药-B发布正面盈利预告：上半年收入最高预计1.55亿元，净亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1118228633","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118228633?lang=zh_cn&edition=full","pubTime":"2026-08-17 08:10","pubTimestamp":1786925441,"startTime":"0","endTime":"0","summary":"8月17日，来凯医药-B公告称，根据截至2026年6月30日止六个月的初步未经审计综合管理账目，公司预计：。公司预计将在2026年8月25日公布正式中期业绩。公司提醒股东及潜在投资者，以上数据仅供参考，买卖公司证券时务请审慎行事。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659814091","title":"来凯医药-B(02105)：LAE002获CDE受理，AKT抑制剂国产重磅将至","url":"https://stock-news.laohu8.com/highlight/detail?id=2659814091","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659814091?lang=zh_cn&edition=full","pubTime":"2026-08-13 08:45","pubTimestamp":1786581907,"startTime":"0","endTime":"0","summary":"阿斯利康开出2026Q2财报，肿瘤学资产AKT抑制剂Truqap俨然成为其中一颗亮眼明星。8月11日，来凯医药-B/齐鲁制药LAE002的NDA已获得CDE受理，预计将在2027年获批并商业化落地。3级不良事件发生率更低，是LAE002作为BIC的一项重要特征。LAE002负责阻断AKT通路这一关键耐药机制，二者联用形成“雄激素合成抑制+通路阻断”的双重打击。CAPItello-281的成功不能线性推出LAE002前列腺癌成功的充分条件，但AKT抑制剂能在前列腺癌兑现价值，已是板上钉钉。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1223082519.USD","CDE","SGDM","XME","GDXJ","BK4017","LU1223082196.USD","SIL","LU1223083913.SGD","02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101653146","title":"来凯医药核心产品LAE002（Afuresertib）新药上市申请获中国国家药监局正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1101653146","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101653146?lang=zh_cn&edition=full","pubTime":"2026-08-12 08:50","pubTimestamp":1786495850,"startTime":"0","endTime":"0","summary":"来凯医药-B（02105.HK）今日宣布，其核心在研药物LAE002（Afuresertib）的新药上市申请（NDA）已获得中国国家药品监督管理局（NMPA）正式受理。这一里程碑式的进展，标志着该药物距离商业化又迈出了关键一步。LAE002作为一种高选择性、口服小分子AKT抑制剂，正被评估用于多种癌症的治疗。此次受理的申请，是基于该药物在相关临床试验中展现出的积极疗效与安全性数据。随着监管审评的推进，来凯医药有望为患者带来全新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658428599","title":"来凯医药：LAE002新药上市申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2658428599","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658428599?lang=zh_cn&edition=full","pubTime":"2026-08-12 08:45","pubTimestamp":1786495519,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166242307","title":"来凯医药-B（02105）LAE 002新药上市申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1166242307","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166242307?lang=zh_cn&edition=full","pubTime":"2026-08-12 08:25","pubTimestamp":1786494328,"startTime":"0","endTime":"0","summary":"2026年8月12日，来凯医药有限公司公告，其自主研发的AKT抑制剂LAE 002用于治疗既往接受内分泌治疗后疾病复发或进展、伴有任何PIK3CA / AKT1 / PTEN改变的HR+ / HER2-局部晚期或转移性乳腺癌患者的新药上市申请已获中国国家药品监督管理局药品审评中心受理。NDA的递交基于公司开展的III期临床试验AFFIRM-205的积极结果。同时，LAE 002表现出良好的安全性及耐受性。公司在公告中提示，LAE 002最终不一定能够成功开发及商业化，提醒投资者在买卖公司证券时保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137506812","title":"来凯医药-B（02105）将于8月25日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1137506812","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137506812?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:11","pubTimestamp":1786093901,"startTime":"0","endTime":"0","summary":"来凯医药-B（02105）8月7日在港交所发布公告称，公司董事会会议定于2026年8月25日（星期二）召开，议程包括审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其对外发布事宜。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143664306","title":"来凯医药-B披露7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1143664306","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143664306?lang=zh_cn&edition=full","pubTime":"2026-08-03 18:32","pubTimestamp":1785753126,"startTime":"0","endTime":"0","summary":"据来凯医药-B2026年8月3日发布的2026年7月股份变动月报表显示，截至7月末，公司股本规模维持不变，未发生新的股份发行、回购注销或库藏股变动。报告期内，已发行股份维持在449,331,350股，无新增发行及无库存股份变动，符合相关公众持股量要求。公司确认已遵守香港联交所《上市规则》及相关法律法规，所有本月内的证券发行或股份变动均经过董事会正式授权。本次月报由公司秘书柯晨煜签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191154605","title":"来凯医药-B于7月15日回购3.90万股，涉资约28.81万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191154605","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191154605?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:50","pubTimestamp":1784112649,"startTime":"0","endTime":"0","summary":"来凯医药-B（股票代码：02105）于2026年7月15日发布翌日披露报表，披露当日通过香港联交所场内回购普通股3.90万股，约占已发行股本0.0087%。回购价格介乎每股7.16港元至7.48港元，总成交金额约28.81万港元。\n回购完成后，公司已发行股本及库藏股数分别为449,331,350股及0股。根据2026年6月5日通过的回购授权，本次回购后公司已累计回购股份总数为219,000股，占授权通过当日已发行股本约0.0487%。公司确认，此次回购已遵守香港联交所相关上市规则及相关法规。\n公告由公司秘书柯晨煜签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"来凯医药-B于7月15日回购3.90万股，涉资约28.81万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131910117","title":"来凯医药-B7月14日回购4万股，涉资约27.67万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1131910117","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131910117?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:36","pubTimestamp":1784028976,"startTime":"0","endTime":"0","summary":"来凯医药有限公司于2026年7月14日发布公告。根据翌日披露报表，来凯医药-B于当日于香港联交所场内回购普通股股份4万股，每股回购最高价为每股7.01港元，最低价为每股6.70港元，合计耗资约27.67万港元。回购完成后，公司已发行股本总数维持在449,331,350股，且无库存股份。公司于2026年6月5日获得最高回购股份数额为44,933,135股的授权，截至目前，已合计回购股份180,000股，占当日已发行股本约0.0401%。公司确认本次回购遵循相关上市规则及相关法例。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"来凯医药-B7月14日回购4万股，涉资约27.67万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":-0.1634},{"period":"1month","weight":-0.1743},{"period":"3month","weight":-0.3642},{"period":"6month","weight":-0.5971},{"period":"1year","weight":-0.6017},{"period":"ytd","weight":-0.5567}],"compareEarnings":[{"period":"1week","weight":-0.033},{"period":"1month","weight":-0.0249},{"period":"3month","weight":0.0035},{"period":"6month","weight":-0.0259},{"period":"1year","weight":-0.0491},{"period":"ytd","weight":-0.0322}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"来凯医药有限公司是一家主要从事癌症、肝脏疾病及肥胖症创新疗法的发现、开发及商业化的投资控股公司。该公司尚处于研发阶段。该公司的在研管线产品包括Afuresertib（LAE002）、LAE001、LAE109、LAE111、LAE112、LAE113、LAE117、LAE118、LAE119、LAE102、LAE103、LAE104、LAE105、LAE106、LAE107、LAE120、LAE123等。Afuresertib是一种三磷酸腺苷（ATP）竞争性AKT抑制剂。LAE001是雄激素合成抑制剂，可同时抑制CYP17A1及CYP11B2。该公司主要在中国、美国、欧洲、韩国等市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.264392},{"month":2,"riseRate":0.666667,"avgChangeRate":0.234103},{"month":3,"riseRate":0.666667,"avgChangeRate":0.090739},{"month":4,"riseRate":0.333333,"avgChangeRate":0.001974},{"month":5,"riseRate":0.666667,"avgChangeRate":0.062052},{"month":6,"riseRate":0,"avgChangeRate":-0.226423},{"month":7,"riseRate":0.25,"avgChangeRate":-0.072516},{"month":8,"riseRate":0.75,"avgChangeRate":0.06659},{"month":9,"riseRate":0.5,"avgChangeRate":0.015167},{"month":10,"riseRate":0.666667,"avgChangeRate":0.10793},{"month":11,"riseRate":1,"avgChangeRate":0.401946},{"month":12,"riseRate":0,"avgChangeRate":-0.176326}],"exchange":"SEHK","name":"来凯医药-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"来凯医药-B,02105,来凯医药-B股票,来凯医药-B股票老虎,来凯医药-B股票老虎国际,来凯医药-B行情,来凯医药-B股票行情,来凯医药-B股价,来凯医药-B股市,来凯医药-B股票价格,来凯医药-B股票交易,来凯医药-B股票购买,来凯医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}